<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01624662</url>
  </required_header>
  <id_info>
    <org_study_id>OPN-FLU-NP-3102</org_study_id>
    <nct_id>NCT01624662</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device</brief_title>
  <official_title>A 16-Week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (Bid) Using a Novel Bi-directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-week, Open-label Extension Phase to Assess Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optinose US Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Optinose US Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study was to compare the efficacy of intranasal administration
      of 100, 200, and 400 μg twice daily (bid) of fluticasone propionate, delivered by the
      Optinose device, with matching placebo in subjects with bilateral nasal polyposis and nasal
      congestion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a randomized, double-blind, placebo-controlled, parallel-group, multicenter study
      designed to assess the efficacy and safety of intranasal administration of 3 doses of
      fluticasone propionate (100, 200, and 400 μg bid), delivered by the Optinose device, in
      subjects with bilateral nasal polyposis and nasal congestion.

      This study consisted of 3 phases. After signing informed consent, subjects who met
      eligibility criteria at Visit 1 (screening) visit entered the study.

        1. Pretreatment phase (single-blind, placebo, run-in): 7 to 14 days duration, to determine
           disease status eligibility and to ensure the subject was able to comply with study
           procedures prior to randomization and enrolment in the double-blind treatment phase

        2. Double-blind treatment phase: 16 weeks duration with 6 scheduled visits starting with
           Visit 2 (Day 1) when eligible subjects were randomized by balance allocation to 1 of 4
           treatment groups and ending at Visit 7 (Week 16)

        3. Open-label extension phase: 8 weeks duration with 1 scheduled visit (Visit 8 [Week 24]),
           during which all subjects received fluticasone propionate 400 mcg BID delivered by the
           Optinose device
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2013</start_date>
  <completion_date type="Actual">July 3, 2015</completion_date>
  <primary_completion_date type="Actual">May 11, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms</measure>
    <time_frame>Baseline, Week 4 of the double-blind treatment phase</time_frame>
    <description>Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing.
0: None
Mild, symptoms clearly present, but minimal awareness, and easily tolerated
Moderate, definite awareness of symptoms that is bothersome but tolerable
Severe, symptoms that are hard to tolerate, cause interference with activities or daily living
During the single-blind run-in phase and during the 16-week, double-blind treatment phase, an electronic diary was provided to each subject. Subjects reported both instantaneous (evaluation of symptom severity immediately preceding the time of scoring) and reflective (evaluation of symptoms severity over the previous 12 hours) scores for nasal congestion/obstruction symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Total Polyp Grade</measure>
    <time_frame>Baseline, Week 16 of the double-blind treatment phase</time_frame>
    <description>Determined by a nasal polyp grading scale score (sum of scores from both nasal cavities) measured by nasoendoscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nasal Congestion/Obstruction Score (7-day Instantaneous Morning)</measure>
    <time_frame>Week 16 of the double-blind treatment phase</time_frame>
    <description>Measured by the 7-day average instantaneous morning diary symptom scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rhinorrhea Score (7-day Instantaneous Morning)</measure>
    <time_frame>Baseline, Week 16 of the double-blind treatment phase</time_frame>
    <description>Change from baseline in rhinorrhea symptoms, as measured by AM and PM diary symptom scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facial Pain or Pressure Score (7-day Instantaneous Morning)</measure>
    <time_frame>Week 16 of the double-blind treatment phase</time_frame>
    <description>Change from baseline in facial pain/pressure symptoms, as measured by AM and PM diary symptom scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyposmia Score (7-day Instantaneous Morning)</measure>
    <time_frame>Week 16 of the double-blind treatment phase</time_frame>
    <description>Change from baseline in hyposmia symptoms, as measured by AM and PM diary symptom scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Nasal Polyp Score</measure>
    <time_frame>Baseline, Week 24 of the open-label extension phase</time_frame>
    <description>Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy.
0: No polyps
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate
Determined by a nasal polyp grading scale score (sum of scores from both nasal cavities measured by nasoendoscopy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polyp Grade of 0 in at Least One Nostril</measure>
    <time_frame>Week 16 of the double-blind treatment phase, Week 24 of the open-label extension phase</time_frame>
    <description>Subjects with a Polyp Grade of 0 (None) in at least one nostril
Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. This outcome measured how many patients with a polyp grad of 0 in at least 1 nostril.
0: No polyps
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sinonasal Outcome Test 22 (SNOT-22) Total Score</measure>
    <time_frame>Baseline, Week 16 of the double-blind treatment phase, Week 24 of the open-label extension phase</time_frame>
    <description>SNOT-22 is a subject-completed questionnaire that consists of 22 questions. The questions on the SNOT-22 efficacy evaluation were used to calculate a total score. 22 questions are divided among 4 subscales: Rhinologic (7 questions), Ear/Facial Symptoms (4 questions), Sleep Function (3 questions), and Psychological Issues (6 questions). Each item was rated on the 5-point scale. The total score can range from 0-110, 0 being the best and 110 being the worst.
0: No problem
Very mild problem
Mild or slight problem
Moderate problem
Severe problem
Problem as bad as it can be</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MOS Sleep-R Score</measure>
    <time_frame>Baseline, Week 16 of the double-blind treatment phase</time_frame>
    <description>The MOS Sleep-R is a brief, self-administered, validated questionnaire designed to measure key aspects of sleep, such as disturbance, adequacy, somnolence, and quantity. The 12-item version with a 4-week recall was used in this study. The score range for the 12-item version is 0 to 100, lower scores indicating better sleep and higher scores indicating worse sleep. The scale yields a Sleep Problem Index and scores on the following 6 subscales: Sleep Disturbance, Snoring, Shortness of Breath or Headache, Sleep Adequacy, Sleep Somnolence, and Sleep Quantity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhinosinusitis Disability Index (RSDI) Total Score</measure>
    <time_frame>Baseline, Week 16 of the double-blind treatment phase</time_frame>
    <description>The RSDI is a subject-completed instrument that evaluates the self-perceived impact of disease specific head and neck disorders. The RSDI has 30 items in 3 domains: Physical (11 items), Functional (9 items), and Emotional (10 items). The RSDI scale ranges from 0-120, 0 being better quality of life and less impact of CRS on daily function and 120 being worse quality of life and more impact of CRS on daily function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36v2 - Mental Component</measure>
    <time_frame>Baseline, Week 16 of the double-blind treatment phase, Week 24 of the open-label extension phase</time_frame>
    <description>The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health. It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health. Each scale range is from 0-100. A lower score means more disability and a higher score means less disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36v2 - Physical Component</measure>
    <time_frame>Baseline, Week 16 of the double-blind treatment phase, Week 24 of the open-label extension phase</time_frame>
    <description>The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health perceptions. It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health. Each scale range is from 0-100. A lower score means more disability and a higher score means less disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants in Each Category of PGIC</measure>
    <time_frame>Week 16 of the double-blind treatment phase, Week 24 of the open-label extension phase</time_frame>
    <description>Patient Global Impression of Change; subject responses to the question: &quot;Since starting the study drug, how would you rate the change in your symptoms?&quot; Percentage includes patients who scored either &quot;very much improved,&quot; &quot;much improved,&quot; or &quot;minimally improved.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Eligible for Nasal Polyp Surgery</measure>
    <time_frame>Week 16 of the double-blind treatment phase; Week 24 of the open-label extension phase</time_frame>
    <description>A subject was considered eligible for surgical intervention if the following conditions were met:
Subject has had moderate symptoms of congestion from nasal polyposis for ≥ 3 months.
Subject continues to suffer from at least moderate symptoms despite use of topical steroids at conventional doses for ≥ 6 weeks.
Subject continues to suffer from at least moderate symptoms despite use (or previous use) of saline lavage for ≥ 6 weeks.
Subject has endoscopically visualized bilateral nasal polyposis of at least moderate severity (nasal polyp grading score ≥ 2 in at least 1 nostril).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Nasal Inspiratory Flow (PNIF)</measure>
    <time_frame>Week 16 of the double-blind treatment phase; Week 24 of the open-label extension phase</time_frame>
    <description>The PNIF is an assessment of nasal passage obstruction and was measured using an In-Check portable nasal inspiratory flow meter. To measure PNIF, a mask was placed over the nose during inspiration and inspiratory flow was recorded. Each subject inhaled 3 times and each measurement was recorded. The PNIF value used was the greatest of the 3 results at each time point.
Change from baseline in Peak Nasal Inspiratory Flow (PNIF)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">323</enrollment>
  <condition>Bilateral Nasal Polyposis</condition>
  <arm_group>
    <arm_group_label>OPN-375 100 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Double-Blind Treatment Phase: OPN-375 100 mcg BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPN-375 200 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Double-Blind Treatment Phase: OPN-375 200 mcg BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPN-375 400 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Double-Blind Treatment Phase: OPN-375 400 mcg BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Double-Blind Treatment Phase: Matched Placebo BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone propionate</intervention_name>
    <description>Delivered via Optinose Exhalation Delivery System</description>
    <arm_group_label>OPN-375 100 mcg</arm_group_label>
    <arm_group_label>OPN-375 200 mcg</arm_group_label>
    <arm_group_label>OPN-375 400 mcg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>OPN-375</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women aged 18 years and older

          -  Women must

               -  be practicing an effective method of birth control (eg, prescription oral
                  contraceptives, contraceptive injections, contraceptive patch, intrauterine
                  device, double-barrier method [eg, condoms, diaphragm, or cervical cap with
                  spermicidal foam, cream, or gel], or male partner sterilization) before entry and
                  throughout the study, or

               -  be surgically sterile (have had a hysterectomy or bilateral oophorectomy, or
                  tubal ligation at least 1 year before screening) or otherwise be incapable of
                  pregnancy, or

               -  be postmenopausal (spontaneous amenorrhea for at least 1 year).

          -  Women of child-bearing potential must have a negative serum beta-human chorionic
             gonadotropin (B-hCG) or urine pregnancy test (depending on local regulations) at the
             screening visit

          -  Must have bilateral nasal polyposis with a grade of 1 to 3 in each of the nasal
             cavities as determined by the Lildholdt scale score measured by nasoendoscopy at both
             screening and baseline visits

          -  Must have at least moderate symptoms of nasal congestion/obstruction as reported by
             the subject for the 7 day period preceding the screening visit

          -  At the baseline visit (Day 1), must have a morning score of at least 2 (moderate) on
             nasal congestion/obstruction recorded on the subject diary for at least 5 of the last
             7 days of the 7 to up to 14 day run-in period

          -  Must demonstrate an ability to correctly complete the daily diary during the run-in
             period to be eligible for randomization

          -  Subjects with comorbid asthma or COPD must be stable with no exacerbations (eg, no
             emergency room visits, hospitalizations, or oral or parenteral steroid use) within the
             3 months before the screening visit. Inhaled corticosteroid use must be limited to
             stable doses of no more than 1,000 μg/day of beclomethasone (or equivalent) for at
             least 3 months before screening with plans to continue use throughout the study.

          -  Must be able to cease treatment with intranasal medications including, but not limited
             to, intranasal steroids, intranasal sodium cromolyn, nasal atropine, nasal ipratropium
             bromide, inhaled corticosteroids (except permitted doses listed above for comorbid
             asthma and COPD) at the screening visit

          -  Must be able to cease treatment with oral and nasal decongestants and antihistamines
             at the screening visit

          -  Must be able to use the OptiNose device correctly; all subjects will be required to
             demonstrate correct use of the placebo device at screening, Visit 1.

          -  Must be capable, in the opinion of the investigator, of providing informed consent to
             participate in the study. Subjects must sign an informed consent document indicating
             that they understand the purpose of and procedures required for the study and are
             willing to participate in the study.

        Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Have complete or near-complete obstruction of the nasal cavities

          -  Inability to achieve bilateral nasal airflow for any reason including nasal septum
             deviation

          -  Inability to have each nasal cavity examined for any reason including nasal septum
             deviation

          -  Nasal septum perforation

          -  Has had more than 1 episode of epistaxis with frank bleeding in the month before the
             screening visit

          -  Have evidence of significant baseline mucosal injury, ulceration or erosion (eg,
             exposed cartilage, perforation) on baseline nasal examination/nasal endoscopy

          -  History of more than 5 sinonasal surgeries for either nasal polyps or nasal/sinus
             inflammation (lifetime)

          -  History of sinus or nasal surgery within 6 months before the screening visit

          -  History of any surgical procedure that prevents the ability to accurately grade polyps

          -  Have symptoms of seasonal allergic rhinitis at screening or baseline and/or, based on
             time of year, would anticipate onset of symptoms within 4 weeks of randomization

          -  Current, ongoing rhinitis medicamentosa (rebound rhinitis)

          -  Have significant oral structural abnormalities, eg, a cleft palate

          -  Diagnosis of cystic fibrosis

          -  History of Churg-Strauss syndrome or dyskinetic ciliary syndromes

          -  Purulent nasal infection, acute sinusitis, or upper respiratory tract infection within
             2 weeks before the screening visit. Potential subjects presenting with any of these
             infections may be rescreened 4 weeks after symptom resolution Note: Subjects who are
             taking prophylactic antibiotics will be allowed to enter the study as long as they
             intend to continue the antibiotics for the duration of the study.

          -  Planned sinonasal surgery during the period of the study

          -  Allergy, hypersensitivity, or contraindication to corticosteroids or steroids

          -  Allergy or hypersensitivity to any excipients in study drug

          -  Exposure to any glucocorticoid treatment with potential for systemic effects (eg,
             oral, parenteral, intra-articular, or epidural steroids, high dose topical steroids)
             within 1 month before the screening visit; except as noted in inclusion criteria for
             subjects with comorbid asthma or COPD

          -  Have nasal candidiasis

          -  Have taken a potent CYP3A4 inhibitor within 14 days before the screening visit.

          -  History or current diagnosis of any form of glaucoma or ocular hypertension (ie, &gt;21
             mmHg)

          -  History of intraocular pressure elevation on any form of steroid therapy

          -  History or current diagnosis of the presence (in either eye) of a cataract

          -  Any serious or unstable concurrent disease, psychiatric disorder, or any significant
             condition that, in the opinion of the investigator could confound the results of the
             study or could interfere with the subject's participation or compliance in the study

          -  A recent (within 1 year of the screening visit) clinically significant history of drug
             or alcohol use, abuse, or dependence that, in the opinion of the investigator could
             interfere with the subject's participation or compliance in the study

          -  Positive urine drug screen at screening visit for drugs of abuse, with the exception
             of prescribed medications for legitimate medical conditions

          -  Have participated in an investigational drug clinical trial within 30 days of the
             screening visit

          -  Employees of the investigator or study center, with direct involvement in the proposed
             study or other studies under the direction of that investigator or study center, as
             well as family members of the employees or the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bensch Clinical Research LLC</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Allergy &amp; Asthma Centers, PC</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced ENT and Allergy</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Asthma and Allergy</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Research Center, LLC</name>
      <address>
        <city>Ocean City</city>
        <state>New Jersey</state>
        <zip>07712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Asthma Research Group</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baker Allergy, Asthma and Dermatology Research Center, LLC</name>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Clinical Research Center</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellingham Asthma, Allergy, and Immunology Clinic</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>June 13, 2012</study_first_submitted>
  <study_first_submitted_qc>June 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2012</study_first_posted>
  <results_first_submitted>October 17, 2017</results_first_submitted>
  <results_first_submitted_qc>December 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 5, 2018</results_first_posted>
  <disposition_first_submitted>July 21, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>September 26, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 27, 2016</disposition_first_posted>
  <last_update_submitted>December 4, 2018</last_update_submitted>
  <last_update_submitted_qc>December 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasal Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>randomization codes sent to PIs</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Matched placebo BID x 16 weeks, then OPN-375 400 mcg BID (open-label) x 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>OPN-375 100 mcg</title>
          <description>OPN-375 100 mcg BID x 16 weeks, then OPN-375 400 mcg BID (open-label) x 8 weeks</description>
        </group>
        <group group_id="P3">
          <title>OPN-375 200 mcg</title>
          <description>OPN-375 200 mcg BID x 16 weeks, then OPN-375 400 mcg BID (open-label) x 8 weeks</description>
        </group>
        <group group_id="P4">
          <title>OPN-375 400 mcg</title>
          <description>OPN-375 400 mcg BID x 16 weeks, then OPN-375 400 mcg BID (open-label) x 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-Blind Treatment Phase (Wks 1-16)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="76"/>
                <participants group_id="P4" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-Label Extension Phase (Wks 17-24)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="72"/>
                <participants group_id="P4" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Matched placebo BID x 16 weeks, then OPN-375 400 mcg BID x 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>OPN-375 100 mcg</title>
          <description>OPN-375 100 mcg BID x 16 weeks, then OPN-375 400 mcg BID x 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>OPN-375 200 mcg</title>
          <description>OPN-375 200 mcg BID x 16 weeks, then OPN-375 400 mcg BID x 8 weeks</description>
        </group>
        <group group_id="B4">
          <title>OPN-375 400 mcg</title>
          <description>OPN-375 400 mcg BID x 16 weeks, then OPN-375 400 mcg BID x 8 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="81"/>
            <count group_id="B3" value="80"/>
            <count group_id="B4" value="82"/>
            <count group_id="B5" value="323"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.7" spread="11.95"/>
                    <measurement group_id="B2" value="46.7" spread="13.72"/>
                    <measurement group_id="B3" value="44.8" spread="12.87"/>
                    <measurement group_id="B4" value="45.0" spread="12.14"/>
                    <measurement group_id="B5" value="45.8" spread="12.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="137"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B5" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="76"/>
                    <measurement group_id="B5" value="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Polyp Grading Score (sum of scores from both nasal cavities)</title>
          <description>Nasal Polyp Grading Score (sum of scores from both nasal cavities measured by nasoendoscopy)
0: No polyps
Mild polyposis – polyps not reaching below the inferior border of the middle turbinate
Moderate polyposis – polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate
Severe polyposis – large polyps reaching below the lower inferior border of the inferior turbinate</description>
          <population>These data are reported for the Full Analysis Set, which included all subjects who received at least one dose of study drug, and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.8" spread="1.08"/>
                    <measurement group_id="B2" value="3.8" spread="0.98"/>
                    <measurement group_id="B3" value="3.9" spread="1.05"/>
                    <measurement group_id="B4" value="3.9" spread="0.98"/>
                    <measurement group_id="B5" value="3.8" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Use of ICS treatment for polyps in past 10 years</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="70"/>
                    <measurement group_id="B5" value="280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous sinus surgery for polyp removal or sinus surgery</title>
          <description>Subjects may have had both sinus surgery and polypectomy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous polyp removal surgery via polypectomy only</title>
          <description>Subjects may have had both sinus surgery and polypectomy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="81"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="323"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nasal Congestion/obstruction Score (7-day instantaneous morning)</title>
          <description>Subjects used an electronic diary to record nasal symptoms each morning for the 7-day period preceding the screening visit, evaluating symptom severity immediately preceding the time of scoring (instantaneous).
Nasal Symptom Score
0: None
Mild – symptoms clearly present, but minimal awareness, and easily tolerated
Moderate – definite awareness of symptoms that is bothersome but tolerable
Severe – symptoms that are hard to tolerate, cause interference with activities or daily living</description>
          <population>These data are reported for the Full Analysis Set, which included all subjects who received at least one dose of study drug, and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.29" lower_limit="1.6" upper_limit="3.0"/>
                    <measurement group_id="B2" value="2.23" lower_limit="1.6" upper_limit="3.0"/>
                    <measurement group_id="B3" value="2.20" lower_limit="1.7" upper_limit="3.0"/>
                    <measurement group_id="B4" value="2.25" lower_limit="1.6" upper_limit="3.0"/>
                    <measurement group_id="B5" value="2.24" lower_limit="1.6" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Rhinorrhea Score (7-day instantaneous morning)</title>
          <description>Subjects used an electronic diary to record nasal symptoms each morning for the 7-day period preceding the screening visit, evaluating symptom severity immediately preceding the time of scoring (instantaneous).
Nasal Symptom Score
0: None
Mild – symptoms clearly present, but minimal awareness, and easily tolerated
Moderate – definite awareness of symptoms that is bothersome but tolerable
Severe – symptoms that are hard to tolerate, cause interference with activities or daily living</description>
          <population>These data are reported for the Full Analysis Set, which included all subjects who received at least one dose of study drug, and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.8" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="B2" value="1.89" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="B3" value="1.86" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="B4" value="1.77" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="B5" value="1.83" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Facial Pain or Pressure Score (7-day instantaneous morning)</title>
          <description>Subjects used an electronic diary to record nasal symptoms each morning for the 7-day period preceding the screening visit, evaluating symptom severity immediately preceding the time of scoring (instantaneous).
Nasal Symptom Score
0: None
Mild – symptoms clearly present, but minimal awareness, and easily tolerated
Moderate – definite awareness of symptoms that is bothersome but tolerable
Severe – symptoms that are hard to tolerate, cause interference with activities or daily living</description>
          <population>These data are reported for the Full Analysis Set, which included all subjects who received at least one dose of study drug, and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.46" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="B2" value="1.46" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="B3" value="1.48" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="B4" value="1.35" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="B5" value="1.44" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hyposmia Score (7-day instantaneous morning)</title>
          <description>Subjects used an electronic diary to record nasal symptoms each morning for the 7-day period preceding the screening visit, evaluating symptom severity immediately preceding the time of scoring (instantaneous).
Hyposmia Score
0: Normal
Slightly impaired
Moderately impaired
Absent</description>
          <population>These data are reported for the Full Analysis Set, which included all subjects who received at least one dose of study drug, and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.47" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="B2" value="2.36" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="B3" value="2.54" lower_limit="0.9" upper_limit="3.0"/>
                    <measurement group_id="B4" value="2.33" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="B5" value="2.43" lower_limit="0.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sinonasal Outcome Test 22 (SNOT-22) Total Score</title>
          <description>SNOT-22 is a subject-completed questionnaire that consists of 22 questions. The questions on the SNOT-22 efficacy evaluation were used to calculate a total score. 22 questions are divided among 4 subscales: Rhinologic (7 questions), Ear/Facial Symptoms (4 questions), Sleep Function (3 questions), and Psychological Issues (6 questions). Each item was rated on the 5-point scale. The total score can range from 0-110, 0 being the best and 110 being the worst.
0: No problem
Very mild problem
Mild or slight problem
Moderate problem
Severe problem
Problem as bad as it can be</description>
          <population>These data are reported for the Full Analysis Set, which included all subjects who received at least one dose of study drug, and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.0" lower_limit="14" upper_limit="94"/>
                    <measurement group_id="B2" value="48.5" lower_limit="9" upper_limit="97"/>
                    <measurement group_id="B3" value="48.1" lower_limit="11" upper_limit="92"/>
                    <measurement group_id="B4" value="47.1" lower_limit="7" upper_limit="103"/>
                    <measurement group_id="B5" value="48.9" lower_limit="7" upper_limit="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical Outcomes Study Sleep Scale Revised (MOS Sleep-R)</title>
          <description>The MOS Sleep-R is a brief, self-administered, validated questionnaire designed to measure key aspects of sleep, such as disturbance, adequacy, somnolence, and quantity. The 12-item version with a 4-week recall was used in this study. The score range for the 12-item version is 0 to 100, lower scores indicating better sleep and higher scores indicating worse sleep. The scale yields a Sleep Problem Index and scores on the following 6 subscales: Sleep Disturbance, Snoring, Shortness of Breath or Headache, Sleep Adequacy, Sleep Somnolence, and Sleep Quantity.</description>
          <population>These data are reported for the Full Analysis Set, which included all subjects who received at least one dose of study drug, and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.7" lower_limit="5.6" upper_limit="86.1"/>
                    <measurement group_id="B2" value="40.9" lower_limit="8.3" upper_limit="94.4"/>
                    <measurement group_id="B3" value="43.0" lower_limit="2.8" upper_limit="86.1"/>
                    <measurement group_id="B4" value="39.1" lower_limit="0.0" upper_limit="77.8"/>
                    <measurement group_id="B5" value="41.2" lower_limit="0.0" upper_limit="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Rhinosinusitis Disability Index (RSDI) Total Score</title>
          <description>The RSDI is a subject-completed instrument that evaluates the self-perceived impact of disease specific head and neck disorders. The RSDI has 30 items in 3 domains: Physical (11 items), Functional (9 items), and Emotional (10 items). The RSDI scale ranges from 0-120, 0 being better quality of life and less impact of CRS on daily function and 120 being worse quality of life and more impact of CRS on daily function.</description>
          <population>These data are reported for the Full Analysis Set, which included all subjects who received at least one dose of study drug, and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.9" lower_limit="4" upper_limit="98"/>
                    <measurement group_id="B2" value="43.9" lower_limit="7" upper_limit="111"/>
                    <measurement group_id="B3" value="39.7" lower_limit="2" upper_limit="89"/>
                    <measurement group_id="B4" value="41.5" lower_limit="0" upper_limit="85"/>
                    <measurement group_id="B5" value="42.5" lower_limit="0" upper_limit="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Short Form (36) Health Survey Version 2 (SF-36v2) - Mental Component</title>
          <description>The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health. It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health. Each scale range is from 0-100. A lower score means more disability and a higher score means less disability.</description>
          <population>These data are reported for the Full Analysis Set, which included all subjects who received at least one dose of study drug, and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.1" lower_limit="21.5" upper_limit="63.58"/>
                    <measurement group_id="B2" value="44.4" lower_limit="12.27" upper_limit="61.03"/>
                    <measurement group_id="B3" value="45.9" lower_limit="19.63" upper_limit="64.81"/>
                    <measurement group_id="B4" value="47.0" lower_limit="20.6" upper_limit="61.63"/>
                    <measurement group_id="B5" value="45.1" lower_limit="12.27" upper_limit="64.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Short Form (36) Health Survey Version 2 (SF-36v2) - Physical Component</title>
          <description>The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health perceptions. It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health. Each scale range is from 0-100. A lower score means more disability and a higher score means less disability.</description>
          <population>These data are reported for the Full Analysis Set, which included all subjects who received at least one dose of study drug, and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.8" lower_limit="26.97" upper_limit="60.07"/>
                    <measurement group_id="B2" value="46.1" lower_limit="28.61" upper_limit="58.86"/>
                    <measurement group_id="B3" value="46.5" lower_limit="29.56" upper_limit="59.43"/>
                    <measurement group_id="B4" value="46.4" lower_limit="22.64" upper_limit="60.32"/>
                    <measurement group_id="B5" value="46.2" lower_limit="22.64" upper_limit="60.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Peak Nasal Inspiratory Flow (PNIF)</title>
          <description>The PNIF is an assessment of nasal passage obstruction and was measured using an In-Check portable nasal inspiratory flow meter. To measure PNIF, a mask was placed over the nose during inspiration and inspiratory flow was recorded. Each subject inhaled 3 times and each measurement was recorded. The PNIF value used was the greatest of the 3 results at each time point.</description>
          <population>These data are reported for the Full Analysis Set, which included all subjects who received at least one dose of study drug, and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119.7" lower_limit="30" upper_limit="370"/>
                    <measurement group_id="B2" value="123.4" lower_limit="30" upper_limit="370"/>
                    <measurement group_id="B3" value="107.6" lower_limit="40" upper_limit="350"/>
                    <measurement group_id="B4" value="122.7" lower_limit="30" upper_limit="370"/>
                    <measurement group_id="B5" value="118.4" lower_limit="30" upper_limit="370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nasal Polyp Surgery Eligibility</title>
          <description>A subject was considered eligible for surgical intervention if the following conditions were met:
Subject has had moderate symptoms of congestion from nasal polyposis for ≥ 3 months.
Subject continues to suffer from at least moderate symptoms despite use of topical steroids at conventional doses for ≥ 6 weeks.
Subject continues to suffer from at least moderate symptoms despite use (or previous use) of saline lavage for ≥ 6 weeks.
Subject has endoscopically visualized bilateral nasal polyposis of at least moderate severity (nasal polyp grading score ≥ 2 in at least 1 nostril).</description>
          <population>These data are reported for the Full Analysis Set, which included all subjects who received at least one dose of study drug, and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="79"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="82"/>
                    <count group_id="B5" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms</title>
        <description>Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing.
0: None
Mild, symptoms clearly present, but minimal awareness, and easily tolerated
Moderate, definite awareness of symptoms that is bothersome but tolerable
Severe, symptoms that are hard to tolerate, cause interference with activities or daily living
During the single-blind run-in phase and during the 16-week, double-blind treatment phase, an electronic diary was provided to each subject. Subjects reported both instantaneous (evaluation of symptom severity immediately preceding the time of scoring) and reflective (evaluation of symptoms severity over the previous 12 hours) scores for nasal congestion/obstruction symptoms.</description>
        <time_frame>Baseline, Week 4 of the double-blind treatment phase</time_frame>
        <population>The Full Analysis Set includes subjects who received at least one dose of study drug and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 mcg</title>
            <description>OPN-375 100 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 mcg</title>
            <description>OPN-375 200 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 mcg</title>
            <description>OPN-375 400 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 7-day Average Instantaneous Morning Diary Congestion/Obstruction Symptoms</title>
          <description>Subjects reported nasal symptoms using the electronic diary twice daily immediately before dosing.
0: None
Mild, symptoms clearly present, but minimal awareness, and easily tolerated
Moderate, definite awareness of symptoms that is bothersome but tolerable
Severe, symptoms that are hard to tolerate, cause interference with activities or daily living
During the single-blind run-in phase and during the 16-week, double-blind treatment phase, an electronic diary was provided to each subject. Subjects reported both instantaneous (evaluation of symptom severity immediately preceding the time of scoring) and reflective (evaluation of symptoms severity over the previous 12 hours) scores for nasal congestion/obstruction symptoms.</description>
          <population>The Full Analysis Set includes subjects who received at least one dose of study drug and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.07"/>
                    <measurement group_id="O2" value="-0.59" spread="0.07"/>
                    <measurement group_id="O3" value="-0.68" spread="0.07"/>
                    <measurement group_id="O4" value="-0.62" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Total Polyp Grade</title>
        <description>Determined by a nasal polyp grading scale score (sum of scores from both nasal cavities) measured by nasoendoscopy</description>
        <time_frame>Baseline, Week 16 of the double-blind treatment phase</time_frame>
        <population>The Full Analysis Set includes subjects who received at least one dose of study drug and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 mcg</title>
            <description>OPN-375 100 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 mcg</title>
            <description>OPN-375 200 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 mcg</title>
            <description>OPN-375 400 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Polyp Grade</title>
          <description>Determined by a nasal polyp grading scale score (sum of scores from both nasal cavities) measured by nasoendoscopy</description>
          <population>The Full Analysis Set includes subjects who received at least one dose of study drug and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" spread="0.11"/>
                    <measurement group_id="O2" value="-1.31" spread="0.11"/>
                    <measurement group_id="O3" value="-1.22" spread="0.11"/>
                    <measurement group_id="O4" value="-1.41" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasal Congestion/Obstruction Score (7-day Instantaneous Morning)</title>
        <description>Measured by the 7-day average instantaneous morning diary symptom scores</description>
        <time_frame>Week 16 of the double-blind treatment phase</time_frame>
        <population>The Full Analysis Set includes subjects who received at least one dose of study drug and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 mcg</title>
            <description>OPN-375 100 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 mcg</title>
            <description>OPN-375 200 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 mcg</title>
            <description>OPN-375 400 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Congestion/Obstruction Score (7-day Instantaneous Morning)</title>
          <description>Measured by the 7-day average instantaneous morning diary symptom scores</description>
          <population>The Full Analysis Set includes subjects who received at least one dose of study drug and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.09"/>
                    <measurement group_id="O2" value="-0.99" spread="0.09"/>
                    <measurement group_id="O3" value="-0.93" spread="0.09"/>
                    <measurement group_id="O4" value="-0.97" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Rhinorrhea Score (7-day Instantaneous Morning)</title>
        <description>Change from baseline in rhinorrhea symptoms, as measured by AM and PM diary symptom scores</description>
        <time_frame>Baseline, Week 16 of the double-blind treatment phase</time_frame>
        <population>Missing data were imputed using the multiple imputation method in the primary analyses for the co-primary efficacy variables. For other efficacy analyses, missing or invalid values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 mcg</title>
            <description>OPN-375 100 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 mcg</title>
            <description>OPN-375 200 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 mcg</title>
            <description>OPN-375 400 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Rhinorrhea Score (7-day Instantaneous Morning)</title>
          <description>Change from baseline in rhinorrhea symptoms, as measured by AM and PM diary symptom scores</description>
          <population>Missing data were imputed using the multiple imputation method in the primary analyses for the co-primary efficacy variables. For other efficacy analyses, missing or invalid values were not imputed.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.09"/>
                    <measurement group_id="O2" value="-1.00" spread="0.09"/>
                    <measurement group_id="O3" value="-0.84" spread="0.09"/>
                    <measurement group_id="O4" value="-0.84" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Facial Pain or Pressure Score (7-day Instantaneous Morning)</title>
        <description>Change from baseline in facial pain/pressure symptoms, as measured by AM and PM diary symptom scores</description>
        <time_frame>Week 16 of the double-blind treatment phase</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 mcg</title>
            <description>OPN-375 100 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 mcg</title>
            <description>OPN-375 200 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 mcg</title>
            <description>OPN-375 400 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Facial Pain or Pressure Score (7-day Instantaneous Morning)</title>
          <description>Change from baseline in facial pain/pressure symptoms, as measured by AM and PM diary symptom scores</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.09"/>
                    <measurement group_id="O2" value="-0.85" spread="0.09"/>
                    <measurement group_id="O3" value="-0.81" spread="0.09"/>
                    <measurement group_id="O4" value="-0.75" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hyposmia Score (7-day Instantaneous Morning)</title>
        <description>Change from baseline in hyposmia symptoms, as measured by AM and PM diary symptom scores</description>
        <time_frame>Week 16 of the double-blind treatment phase</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 mcg</title>
            <description>OPN-375 100 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 mcg</title>
            <description>OPN-375 200 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 mcg</title>
            <description>OPN-375 400 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Hyposmia Score (7-day Instantaneous Morning)</title>
          <description>Change from baseline in hyposmia symptoms, as measured by AM and PM diary symptom scores</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.10"/>
                    <measurement group_id="O2" value="-0.54" spread="0.09"/>
                    <measurement group_id="O3" value="-0.47" spread="0.10"/>
                    <measurement group_id="O4" value="-0.63" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Nasal Polyp Score</title>
        <description>Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy.
0: No polyps
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate
Determined by a nasal polyp grading scale score (sum of scores from both nasal cavities measured by nasoendoscopy)</description>
        <time_frame>Baseline, Week 24 of the open-label extension phase</time_frame>
        <population>The Full Analysis Set includes subjects who received at least one dose of study drug and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 mcg</title>
            <description>OPN-375 100 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 mcg</title>
            <description>OPN-375 200 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 mcg</title>
            <description>OPN-375 400 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Nasal Polyp Score</title>
          <description>Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy.
0: No polyps
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate
Determined by a nasal polyp grading scale score (sum of scores from both nasal cavities measured by nasoendoscopy)</description>
          <population>The Full Analysis Set includes subjects who received at least one dose of study drug and who had baseline assessments of polyp size (nasoendoscopy) and recorded morning nasal congestion/obstruction symptoms.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.06" spread="0.12"/>
                    <measurement group_id="O2" value="-1.60" spread="0.11"/>
                    <measurement group_id="O3" value="-1.48" spread="0.12"/>
                    <measurement group_id="O4" value="-1.75" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Polyp Grade of 0 in at Least One Nostril</title>
        <description>Subjects with a Polyp Grade of 0 (None) in at least one nostril
Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. This outcome measured how many patients with a polyp grad of 0 in at least 1 nostril.
0: No polyps
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate</description>
        <time_frame>Week 16 of the double-blind treatment phase, Week 24 of the open-label extension phase</time_frame>
        <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 mcg</title>
            <description>OPN-375 100 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 mcg</title>
            <description>OPN-375 200 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 mcg</title>
            <description>OPN-375 400 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Polyp Grade of 0 in at Least One Nostril</title>
          <description>Subjects with a Polyp Grade of 0 (None) in at least one nostril
Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. This outcome measured how many patients with a polyp grad of 0 in at least 1 nostril.
0: No polyps
Mild polyposis: polyps not reaching below the inferior border of the middle turbinate
Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate
Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate</description>
          <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (all pts on OPN-375 400 μg BID wks 17-24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sinonasal Outcome Test 22 (SNOT-22) Total Score</title>
        <description>SNOT-22 is a subject-completed questionnaire that consists of 22 questions. The questions on the SNOT-22 efficacy evaluation were used to calculate a total score. 22 questions are divided among 4 subscales: Rhinologic (7 questions), Ear/Facial Symptoms (4 questions), Sleep Function (3 questions), and Psychological Issues (6 questions). Each item was rated on the 5-point scale. The total score can range from 0-110, 0 being the best and 110 being the worst.
0: No problem
Very mild problem
Mild or slight problem
Moderate problem
Severe problem
Problem as bad as it can be</description>
        <time_frame>Baseline, Week 16 of the double-blind treatment phase, Week 24 of the open-label extension phase</time_frame>
        <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 mcg</title>
            <description>OPN-375 100 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 mcg</title>
            <description>OPN-375 200 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 mcg</title>
            <description>OPN-375 400 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Sinonasal Outcome Test 22 (SNOT-22) Total Score</title>
          <description>SNOT-22 is a subject-completed questionnaire that consists of 22 questions. The questions on the SNOT-22 efficacy evaluation were used to calculate a total score. 22 questions are divided among 4 subscales: Rhinologic (7 questions), Ear/Facial Symptoms (4 questions), Sleep Function (3 questions), and Psychological Issues (6 questions). Each item was rated on the 5-point scale. The total score can range from 0-110, 0 being the best and 110 being the worst.
0: No problem
Very mild problem
Mild or slight problem
Moderate problem
Severe problem
Problem as bad as it can be</description>
          <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.70" spread="1.81"/>
                    <measurement group_id="O2" value="-21.14" spread="1.71"/>
                    <measurement group_id="O3" value="-21.43" spread="1.75"/>
                    <measurement group_id="O4" value="-21.05" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (all pts on OPN-375 400 mcg BID wks 17-24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="76"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.45" spread="1.85"/>
                    <measurement group_id="O2" value="-22.89" spread="1.75"/>
                    <measurement group_id="O3" value="-22.92" spread="1.80"/>
                    <measurement group_id="O4" value="-23.21" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MOS Sleep-R Score</title>
        <description>The MOS Sleep-R is a brief, self-administered, validated questionnaire designed to measure key aspects of sleep, such as disturbance, adequacy, somnolence, and quantity. The 12-item version with a 4-week recall was used in this study. The score range for the 12-item version is 0 to 100, lower scores indicating better sleep and higher scores indicating worse sleep. The scale yields a Sleep Problem Index and scores on the following 6 subscales: Sleep Disturbance, Snoring, Shortness of Breath or Headache, Sleep Adequacy, Sleep Somnolence, and Sleep Quantity.</description>
        <time_frame>Baseline, Week 16 of the double-blind treatment phase</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 mcg</title>
            <description>OPN-375 100 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN 375 200 mcg</title>
            <description>OPN-375 200 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN 375 400 mcg</title>
            <description>OPN-375 400 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>MOS Sleep-R Score</title>
          <description>The MOS Sleep-R is a brief, self-administered, validated questionnaire designed to measure key aspects of sleep, such as disturbance, adequacy, somnolence, and quantity. The 12-item version with a 4-week recall was used in this study. The score range for the 12-item version is 0 to 100, lower scores indicating better sleep and higher scores indicating worse sleep. The scale yields a Sleep Problem Index and scores on the following 6 subscales: Sleep Disturbance, Snoring, Shortness of Breath or Headache, Sleep Adequacy, Sleep Somnolence, and Sleep Quantity.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.03" spread="1.52"/>
                    <measurement group_id="O2" value="-14.26" spread="1.46"/>
                    <measurement group_id="O3" value="-15.78" spread="1.50"/>
                    <measurement group_id="O4" value="-14.30" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rhinosinusitis Disability Index (RSDI) Total Score</title>
        <description>The RSDI is a subject-completed instrument that evaluates the self-perceived impact of disease specific head and neck disorders. The RSDI has 30 items in 3 domains: Physical (11 items), Functional (9 items), and Emotional (10 items). The RSDI scale ranges from 0-120, 0 being better quality of life and less impact of CRS on daily function and 120 being worse quality of life and more impact of CRS on daily function.</description>
        <time_frame>Baseline, Week 16 of the double-blind treatment phase</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 mcg</title>
            <description>OPN-375 100 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 mcg</title>
            <description>OPN-375 200 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 mcg</title>
            <description>OPN-375 400 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Rhinosinusitis Disability Index (RSDI) Total Score</title>
          <description>The RSDI is a subject-completed instrument that evaluates the self-perceived impact of disease specific head and neck disorders. The RSDI has 30 items in 3 domains: Physical (11 items), Functional (9 items), and Emotional (10 items). The RSDI scale ranges from 0-120, 0 being better quality of life and less impact of CRS on daily function and 120 being worse quality of life and more impact of CRS on daily function.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.80" spread="1.97"/>
                    <measurement group_id="O2" value="-15.54" spread="1.86"/>
                    <measurement group_id="O3" value="-15.37" spread="1.89"/>
                    <measurement group_id="O4" value="-16.69" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-36v2 - Mental Component</title>
        <description>The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health. It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health. Each scale range is from 0-100. A lower score means more disability and a higher score means less disability.</description>
        <time_frame>Baseline, Week 16 of the double-blind treatment phase, Week 24 of the open-label extension phase</time_frame>
        <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 mcg</title>
            <description>OPN-375 100 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 mcg</title>
            <description>OPN-375 200 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 mcg</title>
            <description>OPN-375 400 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>SF-36v2 - Mental Component</title>
          <description>The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health. It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health. Each scale range is from 0-100. A lower score means more disability and a higher score means less disability.</description>
          <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.86"/>
                    <measurement group_id="O2" value="4.37" spread="0.81"/>
                    <measurement group_id="O3" value="3.88" spread="0.83"/>
                    <measurement group_id="O4" value="3.98" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (all pts on OPN-375 400 mcg BID wks 17-24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.90" spread="0.93"/>
                    <measurement group_id="O2" value="4.07" spread="0.89"/>
                    <measurement group_id="O3" value="4.41" spread="0.92"/>
                    <measurement group_id="O4" value="5.86" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-36v2 - Physical Component</title>
        <description>The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health perceptions. It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health. Each scale range is from 0-100. A lower score means more disability and a higher score means less disability.</description>
        <time_frame>Baseline, Week 16 of the double-blind treatment phase, Week 24 of the open-label extension phase</time_frame>
        <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 mcg</title>
            <description>OPN-375 100 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 mcg</title>
            <description>OPN-375 200 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 mcg</title>
            <description>OPN-375 400 mcg BID x 16 weeks, then OPN-375 400 mcg (open-label) BID x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>SF-36v2 - Physical Component</title>
          <description>The SF-36v2 is a multipurpose, scaled, 36-item, subject-completed validated questionnaire that measures 8 domains of health: limitations in physical activities, limitations in social activities, limitations in usual role activities, bodily pain, general mental health, limitations in usual role activities, vitality, and general health perceptions. It yields scale scores for each of the 8 health domains, and 2 summary measures of physical and mental health. Each scale range is from 0-100. A lower score means more disability and a higher score means less disability.</description>
          <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="77"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.78" spread="0.70"/>
                    <measurement group_id="O2" value="4.27" spread="0.66"/>
                    <measurement group_id="O3" value="4.57" spread="0.67"/>
                    <measurement group_id="O4" value="5.07" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (all pts on OPN-375 400 mcg BID wks 17-24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.50" spread="0.67"/>
                    <measurement group_id="O2" value="5.23" spread="0.64"/>
                    <measurement group_id="O3" value="5.85" spread="0.67"/>
                    <measurement group_id="O4" value="6.06" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants in Each Category of PGIC</title>
        <description>Patient Global Impression of Change; subject responses to the question: &quot;Since starting the study drug, how would you rate the change in your symptoms?&quot; Percentage includes patients who scored either &quot;very much improved,&quot; &quot;much improved,&quot; or &quot;minimally improved.&quot;</description>
        <time_frame>Week 16 of the double-blind treatment phase, Week 24 of the open-label extension phase</time_frame>
        <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo BID x 16 weeks</description>
          </group>
          <group group_id="O2">
            <title>100 mcg Fluticasone Proprionate</title>
            <description>100 mcg fluticasone propionate BID x 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>200 mcg Fluticasone Proprionate</title>
            <description>200 mcg fluticasone propionate BID x 16 weeks</description>
          </group>
          <group group_id="O4">
            <title>400 mcg Fluticasone Prioprionate</title>
            <description>400 mcg fluticasone propionate BID x 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Each Category of PGIC</title>
          <description>Patient Global Impression of Change; subject responses to the question: &quot;Since starting the study drug, how would you rate the change in your symptoms?&quot; Percentage includes patients who scored either &quot;very much improved,&quot; &quot;much improved,&quot; or &quot;minimally improved.&quot;</description>
          <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Very much improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Much improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Minimally improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Minimally worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Much worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very much worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (all pts on OPN-375 400 mcg BID wks 17-24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="76"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Very much improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Much improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Minimally improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Minimally worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Much worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very much worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Eligible for Nasal Polyp Surgery</title>
        <description>A subject was considered eligible for surgical intervention if the following conditions were met:
Subject has had moderate symptoms of congestion from nasal polyposis for ≥ 3 months.
Subject continues to suffer from at least moderate symptoms despite use of topical steroids at conventional doses for ≥ 6 weeks.
Subject continues to suffer from at least moderate symptoms despite use (or previous use) of saline lavage for ≥ 6 weeks.
Subject has endoscopically visualized bilateral nasal polyposis of at least moderate severity (nasal polyp grading score ≥ 2 in at least 1 nostril).</description>
        <time_frame>Week 16 of the double-blind treatment phase; Week 24 of the open-label extension phase</time_frame>
        <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo BID x 16 weeks, then OPN-375 400 mcg BID (open-label) x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 mcg</title>
            <description>OPN-375 100 mcg BID x 16 weeks, then OPN-375 400 mcg BID (open-label) x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 mcg</title>
            <description>OPN-375 200 mcg BID x 16 weeks, then OPN-375 400 mcg BID (open-label) x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 mcg</title>
            <description>OPN-375 400 mcg BID x 16 weeks, then OPN-375 400 mcg BID (open-label) x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Eligible for Nasal Polyp Surgery</title>
          <description>A subject was considered eligible for surgical intervention if the following conditions were met:
Subject has had moderate symptoms of congestion from nasal polyposis for ≥ 3 months.
Subject continues to suffer from at least moderate symptoms despite use of topical steroids at conventional doses for ≥ 6 weeks.
Subject continues to suffer from at least moderate symptoms despite use (or previous use) of saline lavage for ≥ 6 weeks.
Subject has endoscopically visualized bilateral nasal polyposis of at least moderate severity (nasal polyp grading score ≥ 2 in at least 1 nostril).</description>
          <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (all pts on OPN-375 400 mcg BID wks 17-24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="76"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Nasal Inspiratory Flow (PNIF)</title>
        <description>The PNIF is an assessment of nasal passage obstruction and was measured using an In-Check portable nasal inspiratory flow meter. To measure PNIF, a mask was placed over the nose during inspiration and inspiratory flow was recorded. Each subject inhaled 3 times and each measurement was recorded. The PNIF value used was the greatest of the 3 results at each time point.
Change from baseline in Peak Nasal Inspiratory Flow (PNIF)</description>
        <time_frame>Week 16 of the double-blind treatment phase; Week 24 of the open-label extension phase</time_frame>
        <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matched placebo BID x 16 weeks, then OPN-375 400 mcg BID (open-label) x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>OPN-375 100 mcg</title>
            <description>OPN-375 100 mcg BID x 16 weeks, then OPN-375 400 mcg BID (open-label) x 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>OPN-375 200 mcg</title>
            <description>OPN-375 200 mcg BID x 16 weeks, then OPN-375 400 mcg BID (open-label) x 8 weeks</description>
          </group>
          <group group_id="O4">
            <title>OPN-375 400 mcg</title>
            <description>OPN-375 400 mcg BID x 16 weeks, then OPN-375 400 mcg BID (open-label) x 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Nasal Inspiratory Flow (PNIF)</title>
          <description>The PNIF is an assessment of nasal passage obstruction and was measured using an In-Check portable nasal inspiratory flow meter. To measure PNIF, a mask was placed over the nose during inspiration and inspiratory flow was recorded. Each subject inhaled 3 times and each measurement was recorded. The PNIF value used was the greatest of the 3 results at each time point.
Change from baseline in Peak Nasal Inspiratory Flow (PNIF)</description>
          <population>Number of patients analyzed at Week 24 is lower as some patients elected not to participate in the open-label extension phase or withdrew during the open-label extension phase.</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="5.37"/>
                    <measurement group_id="O2" value="26.50" spread="5.12"/>
                    <measurement group_id="O3" value="24.92" spread="5.25"/>
                    <measurement group_id="O4" value="28.64" spread="5.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (all pts on OPN-375 400 mcg BID wks 17-24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="76"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.34" spread="5.42"/>
                    <measurement group_id="O2" value="32.06" spread="5.20"/>
                    <measurement group_id="O3" value="31.87" spread="5.36"/>
                    <measurement group_id="O4" value="33.08" spread="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Double-blind Phase)</title>
          <description>Matched placebo BID x 16 weeks</description>
        </group>
        <group group_id="E2">
          <title>OPN-375 100 mcg (Double-blind Phase)</title>
          <description>OPN-375 100 mcg BID x 16 weeks</description>
        </group>
        <group group_id="E3">
          <title>OPN-375 200 mcg (Double-blind Phase)</title>
          <description>OPN-375 200 mcg BID x 16 weeks</description>
        </group>
        <group group_id="E4">
          <title>OPN-375 400 mcg (Double-blind Phase)</title>
          <description>OPN-375 400 mcg BID x 16 weeks</description>
        </group>
        <group group_id="E5">
          <title>OPN-375 400 mcg (Open-label Phase)</title>
          <description>OPN-375 400 mcg (open-label) BID x 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Meningitis and Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Positional vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="60" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>URTI</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Epistaxis (identified by investigator on routine nasal endoscopy)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Epistaxis (spontaneously reported by subject)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Nasal mucosal disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Nasal septum disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Nasal septum ulceration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President Global Clinical Operations &amp; Outsourcing</name_or_title>
      <organization>OptiNose</organization>
      <phone>267-364-3508</phone>
      <email>jennifer.carothers@optinose.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

